asparaginase

(redirected from L-asparaginase)
Also found in: Dictionary, Thesaurus, Medical.
Related to L-asparaginase: methotrexate, cyclophosphamide, etoposide, vincristine

asparaginase

[‚as·pə′raj·ə‚nās]
(biochemistry)
An enzyme that catalyzes the hydrolysis of asparagine to asparaginic acid and ammonia.
References in periodicals archive ?
1974, "Amino acid sequence of L-asparaginase from Escherichia coli," J.
Most cancer cells, however, resemble normal cells in their ability to synthesize L-asparagine, and so L-asparaginase has little activity on them.
The L-asparaginase activity assay developed at AIBioTech[TM] is intended to help physicians identify patients experiencing "silent inactivation" of asparaginase as well as to ensure that adequate asparaginase activity is present during treatment.
As an NSCS partner, QmedRx (PCAB Accredited Pharmacy) follows strict USP-795 and USP-797 standards of pharmacy practices and procedures, making their compounded L-Asparaginase the highest quality product in the market today.
Of note is a research agreement signed with the MD Anderson Cancer Center in the US, which has identified a biomarker for the prediction of L-asparaginase on solid tumors.
GRASPA([R]) is a new enzyme formulation of L-asparaginase with a safer and broader range of clinical application compared to existing forms thanks to the entrapment of the enzymes and protection inside homologous red blood cells.
This agreement between Alize Pharma and EUSA Pharma, a worldwide leader in the development and marketing of L-asparaginase products, is excellent news for us, for our investors and for ALL patients," said Alize Pharma ' s President and founder, Thierry Abribat .
OPi SA, Pharmaceuticals for Rare Diseases and the UK Health Protection Agency (HPA) announce today that they have entered into a world-wide licensing and supply agreement on Erwinase(R) (crisantaspase), L-asparaginase derived from Erwinia chrysanthemi.
ERYtech Pharma, a specialty pharma company located in France and in USA (Philadelphia), is pleased to announce a collaborative research agreement in the field of personalized medicine focusing on ERYtech's flagship product, GRASPA([R]), which consists of red blood cell-encapsulated L-asparaginase (L-ASP).
L-asparaginase is given to ALL patients to ensure depletion of asparagine that is circulating in the blood.
GRASPA([R]) is a new enzyme formulation of L-asparaginase with a safer and broader range of clinical use's compared to existing forms due to the enzymes entrapment and protection inside the homologous red blood cell.